Status:
TERMINATED
Safety of VSL#3 in Adult Asthmatics
Lead Sponsor:
University of Maryland, Baltimore
Collaborating Sponsors:
National Center for Complementary and Integrative Health (NCCIH)
Conditions:
Asthma
Eligibility:
All Genders
18-64 years
Phase:
PHASE1
PHASE2
Brief Summary
We are proposing to test the safety of the probiotic, VSL#3, in a placebo controlled double blind safety study in 30 asthmatic adults. This adult safety trial was requested by the FDA IND review of a ...
Detailed Description
The monitored parameters that will be assessed at each clinic visit or phone call include: 1. the number of days with asthma related symptoms of cough, wheeze, dyspnea, awakening at night, and exerci...
Eligibility Criteria
Inclusion
- Adults age 18-64 years old.
- Doctor diagnosis of mild persistent asthma. Persistent asthma is defined by NAEPP guidelines as asthma symptoms (cough/wheeze/dyspnea/exercise limitation)of greater than 2 times/week daytime or greater than 2 times/month at night over the previous month but less than continual and less than 5 nights/week.
- FEV1 greater than 60% predicted for age/gender/race/height based on normative data.
- No unscheduled asthma related health visit in the 1 month prior to enrollment
- School or work days missed less than or equal to 2 in the previous month for asthma.
- Albuterol use less than 8 doses (2 puffs or one neb) in past week.
- Ability to speak and understand English.
- Telephone access.
- Women of childbearing potential must confirm that they will use birth control while in the study and have a negative urine pregnancy screen at baseline.
Exclusion
- Pregnant women, prisoners.
- Chronic illness (other than asthma, allergic rhinitis and eczema) such as renal disease, diabetes, hypertension or terminal disease or abnormal vital signs: T\> 100.3F, HR\>130 bpm, SBP\>155 mmHg, or DBP\>100 mmHg, RR\>25 bpm, or pox\<93% room air.
- Unable to perform spirometry, necessary for lung function assessment.
- Received probiotic in past 6 months.
- Subject or household member has immunosuppression such as HIV, history of organ transplantation, present cancer or chemotherapy, primary immune disease, or is taking an immune modulating drug.
- Severe persistent asthmatics who have continual daily or frequent (greater than 5 nights/week) asthma symptoms and/or FEV1 less than 60% predicted .
- Diarrhea or constipation (symptoms more than once in the past week)
- Unable to feed orally or to consume cornstarch
- Lung disease other than asthma (e.g. COPD, cystic fibrosis, lung cancer, bronchiectasis, interstitial lung disease).
- Subjects at increased risk of developing infective endocarditis such as those with a history of cardiac surgery, IV drug abuse, recent invasive medical procedures or dental work (recent = last month).
- Allergy to Vancomycin or Cefepime. The parameters of intestinal barrier function, intestinal flora, serum inflammatory cytokines, IgE, will have no exclusion ranges as these will be collected over time on product as a way of describing the population characteristics of study participants.
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT00852124
Start Date
February 1 2007
End Date
January 1 2013
Last Update
April 20 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Maryland Baltimore
Baltimore, Maryland, United States, 21201